Edition:
United Kingdom

Tamara Mathias

Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug

13 Dec 2019

Shares of Sarepta Therapeutics Inc soared 31% on Friday after U.S. regulators shocked Wall Street by approving the company's treatment for a muscle-wasting disorder less than four months after rejecting the drug over safety concerns.

Sarepta shares surge after surprise approval of DMD drug

13 Dec 2019

Shares of Sarepta Therapeutics Inc soared 32% on Friday after U.S. regulators shocked Wall Street by reversing their rejection of its muscle-wasting disorder therapy less than four months ago, to allow the drug's immediate launch.

Merck pushes deeper into targeted cancer therapy with $2.7 billion ArQule deal

09 Dec 2019

Merck & Co Inc said on Monday it would buy ArQule Inc for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.

Alexion Pharma rejects Elliott's push for 'proactive sale'

06 Dec 2019

Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders.

FDA declines to approve Enzyvant regenerative therapy on manufacturing concerns

05 Dec 2019

Privately held drug developer Enzyvant said on Thursday the U.S. Food and Drug Administration declined to approve its regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about its manufacturing.

Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel

03 Dec 2019

Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months.

Tear gas used for crowd control in Hong Kong poses health, environmental risks

02 Dec 2019

The use of tear gas to control crowds of protesters in the Chinese-ruled city of Hong Kong could have dangerous effects on health and the environment, a group of academics warns.

Drinking-related liver disease and deaths on the rise in U.S.

29 Nov 2019

(Reuters Health) - Americans today are expected to live shorter lives than just a few years ago, in contrast with trends seen in other developed nations, and rising deaths from alcohol-related liver disease may be partly to blame, researchers say.

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

27 Nov 2019

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

World News